Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients with inadequately treated painful diabetic peripheral neuropathy did not meet its primary efficacy endpoint. READ MORE
Source: Marketwatch
May
01
Comments are closed.